Related Experiment Video
Updated: Sep 20, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Tumor Genotype Is Shaping Immunophenotype and Responses to Immune Checkpoint Inhibitors in Solid Tumors
Kathrina L Marcelo-Lewis1, Shhyam Moorthy2, Ecaterina Ileana-Dumbrava2
1Department of Thoracic/ Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
A major breakthrough in cancer treatment was ushered in by the development of immune checkpoint blockade therapy such as anti-CTLA4 antibody and anti-PD-1 and anti-programmed cell death-ligand 1 antibodies that are now approved for use in an increasing number of malignancies. Despite the relative success of immune checkpoint inhibitors with certain tumor types, many patients still fail to respond to such therapies, and the field is actively trying to understand the mechanisms of resistance, intrinsic or acquired, to immune checkpoint blockade. Herein, we discuss the roles that somatic genomic mutations in oncogenic pathways play in immune editing, as well as some of the current approaches toward improving response to immunotherapy.
Insights
Immune checkpoint inhibitors have revolutionized cancer treatment, but resistance remains a challenge. Understanding how cancer mutations affect immune responses is key to improving patient outcomes with immunotherapy.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Immune checkpoint blockade therapy, including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies, represents a significant advancement in cancer treatment.
- These immunotherapies are approved for various malignancies, demonstrating considerable success in certain tumor types.
Purpose of the Study:
- To explore the role of somatic genomic mutations in oncogenic pathways within the context of immune editing.
- To discuss current strategies aimed at overcoming resistance and enhancing patient response to immune checkpoint blockade therapy.
Main Methods:
- Review of existing literature on immune checkpoint inhibitors.
- Analysis of the interplay between somatic mutations, oncogenic pathways, and immune responses.
- Discussion of emerging therapeutic approaches.
Main Results:
- Somatic genomic mutations can influence immune editing processes, impacting the effectiveness of immunotherapies.
- Mechanisms of intrinsic and acquired resistance to immune checkpoint blockade are actively being investigated.
- Understanding these mechanisms is crucial for developing more effective treatment strategies.
Conclusions:
- Further research into the genetic underpinnings of cancer is essential for optimizing immunotherapy.
- Targeting specific mutations and pathways may enhance patient response to immune checkpoint inhibitors.
- Personalized approaches hold promise for improving outcomes in patients resistant to current treatments.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:17The Tumor Microenvironment